SEC Form 4 · accession 0001179110-18-010999

ENDOCYTE INC · ECYT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Vice President of Research

Period of report

Aug 28, 2018

Accepted (ET)

Aug 29, 2018 · 5:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001235007

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Aug 28, 2018	M	12,670	$2.54	A	143,051	D
Common Stock^F2	Aug 28, 2018	S	12,670	$20.0002	D	130,381	D
Common Stock^F1	Aug 29, 2018	M	4,696	$2.54	A	135,077	D
Common Stock^F3	Aug 29, 2018	S	4,696	$20.00	D	130,381	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F1,F4	$2.54	Aug 28, 2018	M	12,670	D	—	Mar 5, 2019	Common Stock	12,670	24,696	D
Stock Option (right to buy)^F1,F4	$2.54	Aug 29, 2018	M	4,696	D	—	Mar 5, 2019	Common Stock	4,696	20,000	D

F1The stock options were exercised pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
F2Represents the sale of 12,670 shares in multiple transactions, ranging in price from $20.0000 to $20.0100, resulting in a weighted-average sale price per share of $20.0002. The reporting person will provide, upon request by SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
F3The shares were sold pursuant to a written plan specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
F4The option is fully vested and immediately exercisable.